PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport® (abobotulinumtoxinA) in Pediatric Lower ...
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) Patients with stage IIIB-IVM1c unresectable ...
The purpose of these two identical studies is to assess the efficacy, safety, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active moderate to severe ...
A groundbreaking double-blind study announced on May 3rd by Los Angeles-based EZC Pak has uncovered a promising alternative to antibiotics for treating upper respiratory infections (URIs). This ...
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery ...
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
TipRanks on MSN
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled A Phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback